Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.
about
The Utility of Molecular Imaging in Prostate CancerPatient experience in the treatment of metastatic castration-resistant prostate cancer: state of the scienceSerum early prostate cancer antigen (EPCA) level and its association with disease progression in prostate cancer in a Chinese populationOverexpression of Pleomorphic Adenoma Gene-Like 2 Is a Novel Poor Prognostic Marker of Prostate CancerRisk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial.Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomyCigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database.End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic reviewUpdate on the management of prostate cancer with goserelin acetate: patient perspectivesBiochemical markers of bone turnover and clinical outcomes in men with prostate cancerThe Metabolic Syndrome and Biochemical Recurrence following Radical Prostatectomy.An update on the changing indications for androgen deprivation therapy for prostate cancer.Genomic "Dark Matter" in Prostate Cancer: Exploring the Clinical Utility of ncRNA as Biomarkers.Postoperative radiotherapy after radical prostatectomy: indications and open questionsA pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy.Genetic variants of the autophagy pathway as prognostic indicators for prostate cancer.Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy.Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer.Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy.Clinical significance and treatment of biochemical recurrence after definitive therapy for localized prostate cancer.Long-term outcomes of salvage radiotherapy for PSA-recurrent prostate cancer: validation of the Stephenson nomogram.Follistatin as potential therapeutic target in prostate cancer.Profiling serum HER-2/NEU in prostate cancer.Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer.The Effects of Social Support on Health-Related Quality of Life of Patients with Metastatic Prostate Cancer.Australian validation of the Cancer of the Prostate Risk Assessment Post-Surgical score to predict biochemical recurrence after radical prostatectomy.A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study.Can diffusion-weighted magnetic resonance imaging predict a high Gleason score of prostate cancer?Prostate-specific antigen kinetics after failure of primary prostate cancer therapy: a valuable prognostic factor.Subclassification of high-risk clinically organ-confined prostate cancer for early cancer-specific mortality after radical prostatectomy.Metabolic syndrome, dyslipidemia and prostate cancer recurrence after primary surgery or radiation in a veterans cohort.Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.Salvage radiation therapy 11 years after a radical prostatectomy.External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score for Prediction of Disease Recurrence after Radical Prostatectomy.Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate CancerChemokine markers predict biochemical recurrence of prostate cancer following prostatectomy.Salvage pelvic lymph node dissection in recurrent prostate cancer: surgical and early oncological outcome.Prostate-specific antigen measured 3 months after radical prostatectomy as a new predictor of biochemical recurrence.The probability of Gleason score upgrading between biopsy and radical prostatectomy can be accurately predicted.A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer.
P2860
Q26764746-BAC3F508-5D58-448A-B566-70A666E0C162Q26772883-72D58CD5-DA7B-4870-8E83-E707AB7B3E5EQ28478038-E15223BE-DEAB-4849-AEC3-B8065E1FDB91Q28553603-18C43667-76FD-4424-A994-759996467578Q30586073-E0A815BB-583B-466F-A9F0-9BC9E84DB89EQ34091402-EB490E1C-EAAE-4C29-A5FB-E1F696F0616EQ34108249-BFF590A3-531F-4220-98C4-27106757C130Q34367585-A3F39DBE-AF56-4CBB-AE74-287E35309AF9Q34418403-9948DA5D-A7CE-4CDE-AE12-5E24B571396BQ35022212-2E2D2ABA-45D0-4124-BAC9-9EDAC9CC8D44Q35390159-BD605BCB-105C-4967-A985-B6CD58A1907DQ35549863-3775DE29-5F85-4670-9A7E-F5EFF1F99876Q35771477-DE6BF4D0-C69F-4A0F-8066-EB93118FFDE7Q35863963-51B3867F-2103-43C2-9BB7-4B2A73E45BA1Q35995359-A655B4BE-5839-45FD-8C29-2C7E0967AC20Q36056250-EB6E7B78-A093-4C70-88F3-6CDC3DB8FCEEQ37086821-55B1901A-CF38-42D1-833C-3A3A11BD99BAQ37347492-E31C99B0-84A8-412D-AB6A-DC7231E61A25Q37385840-DBC50612-39E8-47E5-B2B2-49BD99CA288EQ37460247-2BC59D66-A733-478A-804B-012529D10769Q37744804-882EE358-46CA-4A95-A9DB-4DC3D3BA96DDQ38086102-AE822A4C-71D1-419A-A4EF-50A18ECA1673Q38174595-2EBE631A-F0A7-4E47-BCE1-606C77A86660Q38438248-F514299F-A5F7-4A64-A712-596F572D7B61Q38547014-3ED298D1-31C6-4979-A3D9-8CD56DC602F7Q38805275-E1B8E287-B174-4B62-A150-F81F468989E2Q39581362-5A9F778F-3566-4FB5-A98C-E80EA45EC7B9Q39946559-34E592F2-BA12-43FE-A667-A46B1A8793C3Q40188921-7DB8FBEA-9019-4E56-BDF4-DDF30E737338Q40743419-C4E34D56-F5A9-4593-A110-A9E84FFF7AF9Q41139603-2F23CB89-89F1-4D66-BC5A-89BAE5C2F219Q41339007-BE63D7D1-6B8C-4D4E-9B6A-58333DB6F95BQ41469013-15A40C36-886F-4FBC-8CA5-5D34AFC155BDQ41643572-9A9287AF-7517-4A28-BBC9-EEB0F7BADDA1Q42379563-8C2440F7-22A0-41C2-88DD-FA9225990676Q42660306-47A20A99-04C9-4397-ACAB-EBF95A51E473Q42785526-B9F37B45-7CDE-448D-BBE6-FA643BE2CBB9Q43429179-D7978FFF-B76A-4C9F-9E25-6232C9BCD6F7Q43915762-BB165303-A75C-43B3-BCE9-8A50397E9095Q44166558-7F72C547-5618-4E09-8B9B-AE3E81C9A79C
P2860
Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Natural history of biochemical ...... essment for secondary therapy.
@ast
Natural history of biochemical ...... essment for secondary therapy.
@en
type
label
Natural history of biochemical ...... essment for secondary therapy.
@ast
Natural history of biochemical ...... essment for secondary therapy.
@en
prefLabel
Natural history of biochemical ...... essment for secondary therapy.
@ast
Natural history of biochemical ...... essment for secondary therapy.
@en
P2093
P1433
P1476
Natural history of biochemical ...... essment for secondary therapy.
@en
P2093
Andrew J Stephenson
Eric A Klein
Matthew N Simmons
P304
P356
10.1016/J.EURURO.2007.01.015
P407
P577
2007-01-12T00:00:00Z